首頁 > 市場調查報告書 > 製藥

神經疾病疼痛

市場調查報告書

商品編碼

1808945

神經痛治療市場，依治療、最終用途、國家及地區 - 2025 年至 2032 年全球產業分析、市場規模、市場佔有率及預測

Neuralgia Treatment Market, By Treatment, By End Use, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日期: 2025年09月04日 | 出版商:

AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年神經痛治療市場規模價值 26.9591 億美元，2025 年至 2032 年的複合年成長率為 7.20%。

神經痛治療是指治療因損傷、感染或其他疾病引起的慢性神經疼痛的一種疾病。神經痛治療旨在緩解症狀、減緩病情進展並避免併發症。

神經痛治療市場-市場動態

慢性病盛行率不斷上升推動市場成長

糖尿病等慢性疾病的日益普及預計將推動神經痛治療市場的未來成長。慢性疾病是指持續一年或更長時間，需要持續醫療照護、限制日常活動或兩者兼而有之的疾病。糖尿病是一種以高血糖（也稱為血糖）為特徵的慢性代謝性疾病。神經痛治療有助於治療糖尿病神經病變，這是一種可能發生在糖尿病患者身上的神經損傷。例如，設在瑞士的聯合國專門機構世界衛生組織報告稱，2023年9月全球死亡人數為4,100萬人，佔全球非傳染性疾病（NCD）或慢性疾病導致的死亡總數的74%。因此，糖尿病等慢性疾病的日益普及正在推動神經痛治療市場的成長。

神經痛治療市場-關鍵見解

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 7.20%。

根據治療細分，預計 2025 年手術的市場佔有率將達到最高。

根據最終用途細分，2025 年最常見的最終用途將是醫院和診所。

2025 年，北美將成為收入最高的地區。

神經痛治療市場-細分分析：

全球神經痛治療市場根據治療、最終用途和地區進行細分。

根據治療方法，市場分為兩類：藥物治療和手術治療。到2025年，手術治療將佔據市場主導地位。對精準、非侵入性治療方案（例如機器人放射外科手術）日益成長的需求是該領域的主要驅動力。這些先進的方法可以有針對性地緩解疼痛，同時減少對傳統藥物或侵入性手術的需求。機器人放射外科手術不僅精度高，而且對周圍組織的損傷最小，進而改善患者的治療效果。隨著患者尋求更安全、更有效的治療方案，市場正受到向微創治療轉變的推動。

根據最終用途，市場分為三類：醫院和診所、門診手術中心和其他。到2025年，醫院和診所將佔據最大的市場收入佔有率。醫院和診所採用先進的非侵入性技術，可實現更精準、更有針對性的治療，進而推動市場成長。這些技術減少了對侵入性手術的需求，從而縮短了復原時間，減輕了患者的不適感。醫療保健提供者可以更精準地獲得更好的治療效果，從而提高患者的整體滿意度。這種向微創治療方案的轉變增加了對先進神經痛治療的需求。

神經痛治療市場-地理洞察

由於糖尿病患者中糖尿病性疼痛性神經病變 (PDN) 等慢性疼痛疾病的盛行率不斷上升，推動了對非侵入性有效治療的需求，北美神經痛治療市場將在 2025 年佔據最大佔有率。美國食品藥物管理局 (FDA) 於 2024 年 1 月批准了 Neuralace Medical 的非侵入性 Axon 療法，用於治療糖尿病性疼痛性神經病變。這項批准將推動糖尿病患者肢體神經痛的疼痛管理。 Axon 療法透過低壓電脈衝刺激神經，無需藥物或手術即可減輕疼痛。該療法更安全、更便捷，可望幫助許多患有慢性神經性疼痛的糖尿病患者。

亞太地區神經痛治療市場將在預測期內成長最快。監管機構批准的創新治療方案增加了該地區神經修復手術的選擇。再生醫學公司Orthocell Ltd.已獲得新加坡衛生科學局（HSA）的Remplir監管批准，允許其於2025年第一季開始銷售。知名醫療器材供應商Device Technologies在獲得批准之前已在澳洲和紐西蘭分銷Remplir。 Remplir膠原蛋白包覆療法可改善神經修復手術。

神經痛治療市場-競爭格局：

神經痛治療市場競爭適中，輝瑞、葛蘭素史克、諾華和百健在抗驚厥藥、抗憂鬱藥和局部止痛藥領域佔據主導地位。市場正在見證更多合作與併購，例如Globus Medical收購Nevro，以擴大其神經調節產品線。隨著醫療服務可近性的改善和治療費用的降低，亞太地區的區域性參與者也不斷成長。總體而言，標靶藥物療法、微創疼痛管理解決方案以及個人化治療方法的日益普及正在塑造神經痛治療市場格局。

介紹
- 按地區分類的細分市場佔有率分析
北美洲
- 概述
- 北美神經痛治療主要製造商
- 北美市場規模及預測（按國家/地區）
- 北美市場規模及預測（按治療類型）
- 北美市場規模和預測，按最終用途
- 美國
- 加拿大
歐洲
- 概述
- 歐洲神經痛治療主要製造商
- 歐洲市場規模及預測（按國家/地區）
- 歐洲市場規模及預測（按治療類型）
- 歐洲市場規模和預測，按最終用途
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 瑞典
- 俄羅斯
- 波蘭
- 歐洲其他地區
亞太地區 (APAC)
- 概述
- 亞太地區神經痛治療主要製造商
- 亞太地區市場規模及預測（依國家）
- 亞太地區市場規模及預測（依治療類型）
- 亞太地區市場規模及預測（依最終用途）
- 中國
- 印度
- 日本
- 韓國
- 澳洲
- 印尼
- 泰國
- 菲律賓
- 亞太地區其他地區
拉丁美洲（LATAM）
- 概述
- 拉丁美洲神經痛治療主要製造商
- 拉丁美洲市場規模及預測（按國家/地區）
- 拉丁美洲市場規模及預測（依治療類型）
- 拉丁美洲市場規模及預測（依最終用途）
- 巴西
- 墨西哥
- 阿根廷
- 哥倫比亞
- 拉丁美洲其他地區
中東和非洲（MEA）
- 概述
- 中東和非洲神經痛治療主要製造商
- MEA 市場規模及預測（依國家/地區）
- MEA 市場規模及預測（以處理方式）
- MEA 市場規模及預測（依最終用途）
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 土耳其
- 阿爾及利亞
- 埃及
- MEA 其餘地區

第 10 章：神經痛治療產業主要供應商分析

競爭基準化分析
- Competitive Dashboard
- Competitive Positioning
公司簡介
- GSK plc.
- Pfizer Inc.
- Biogen
- Zydus Group (Cadila Healthcare Limited)
- H. Lundbeck A/S
- Novartis AG
- Others

第 11 章：360 度分析師視角

第 12 章：附錄

研究方法
參考
縮寫
免責聲明
聯絡我們

簡介目錄

Product Code: ANV5576

Neuralgia Treatment Market size was valued at US$ 2,695.91 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

Neuralgia treatment is the treatment of a medical condition characterized by chronic pain in the nerves that can be caused by injury, infection, or other medical issues. Neuralgia treatment is used to alleviate symptoms, slow the progression of the condition, and avoid complications.

Neuralgia Treatment Market- Market Dynamics

Growing Prevalence Of Chronic Diseases Fuels Market Growth

The increasing prevalence of chronic diseases, such as diabetes, is expected to drive future growth in the neuralgia treatment market. Chronic diseases are problems that last a year or more and require ongoing medical care, limit daily activities, or both. Diabetes is a chronic metabolic condition characterized by high blood glucose, also known as blood sugar. Neuralgia treatment can help with diabetic neuropathy, which is nerve damage that can occur in people with diabetes. For instance, the World Health Organization, a United Nations specialized agency based in Switzerland, reported 41 million deaths in September 2023, accounting for 74% of all deaths caused by noncommunicable diseases (NCDs) or chronic diseases worldwide.As a result, the increasing prevalence of chronic diseases such as diabetes is driving the growth of the neuralgia treatment market.

Neuralgia Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)

According to treatment segmentation, the year 2025 is expected to see the highest market share for surgery.

According to End Use segmentation, the most common End Use in 2025 will be hospitals and clinics.

North America ranked as the top revenue-generating region in 2025.

Neuralgia Treatment Market- Segmentation Analysis:

The Global Neuralgia Treatment Market is segmented on the basis of Treatment, End Use, and Region.

The market is divided into two categories based on Treatment: Drug Based, and Surgery. The surgery segment will dominate the market in 2025. The growing demand for precise, non-invasive treatment options, such as robotic radiosurgery, is a major driver in the segment. These advanced methods provide targeted pain relief while reducing the need for traditional medications or invasive surgeries. Robotic radiosurgery allows for high accuracy while causing minimal damage to surrounding tissues, which improves patient outcomes. The market is being driven by a shift toward less invasive treatments, as patients seek safer, more effective alternatives.

The market is divided into three categories based on End Use: Hospital & Clinics, Ambulatory Surgery Centers, and Others. In 2025, the hospital and clinics segment will account for the largest market revenue share. Adoption of advanced, non-invasive technologies in hospitals and clinics drives market growth by allowing for more precise and targeted treatments. These technologies reduce the need for invasive procedures, resulting in faster recovery times and less patient discomfort. Healthcare providers can achieve better results with greater precision, increasing overall patient satisfaction. This shift toward less invasive options increases demand for advanced neuralgia treatments.

Neuralgia Treatment Market- Geographical Insights

North America neuralgia treatment market will hold the largest share in 2025 due to the rising prevalence of chronic pain conditions like painful diabetic neuropathy (PDN) among diabetics, driving demand for non-invasive, effective treatments. The FDA approved Neuralace Medical's non-invasive Axon Therapy for painful diabetic neuropathy in January 2024. This approval advances pain management for diabetics with limb nerve pain. Axon Therapy stimulates nerves with low-voltage electrical pulses to reduce pain without drugs or surgery. The therapy may help many diabetics with chronic neuropathic pain by being safer and more accessible.

Asia Pacific neuralgia treatment market to grow fastest over forecast period. Innovative treatment solutions approved by regulators have increased nerve repair surgery options in the region. Orthocell Ltd., a regenerative medicine company, received regulatory approval from Singapore's Health Sciences Authority (HSA) for Remplir, allowing sales to begin in Q1 of CY25. Device Technologies, a well-known medical device supplier, distributed Remplir in Australia and New Zealand before this approval. Remplir collagen wraps improve nerve repair surgery.

Neuralgia Treatment Market- Competitive Landscape:

The Neuralgia Treatment Market is moderately competitive, with Pfizer, GlaxoSmithKline, Novartis, and Biogen dominating the pharmaceutical segment with anticonvulsants, antidepressants, and topical analgesics. The market is seeing more collaboration and mergers, such as Globus Medical's acquisition of Nevro, to expand its neuromodulation offerings. Regional players in Asia-Pacific are also gaining ground as healthcare access improves and therapies become more affordable. Overall, the landscape is shaped by advances in targeted drug therapies, minimally invasive pain management solutions, and the growing use of personalized treatment approaches.

Recent Developments:

In January 2024, Zydus Lifesciences has received final FDA approval for its generic Gabapentin tablets for the treatment of postherpetic neuralgia (PHN). The approval covers 300 mg and 600 mg once-daily doses of a drug used to relieve pain after shingles.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEURALGIA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GSK plc.
Pfizer Inc.
Biogen
Zydus Group (Cadila Healthcare Limited)
H. Lundbeck A/S
Novartis AG
Others

GLOBAL NEURALGIA TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

Drug Based
Anticonvulsant Medicines
Tricyclic Antidepressants
Surgery
Radiofrequency Thermal Lesioning
Stereotactic Radiosurgery
Microvascular Decompression
Others

GLOBAL NEURALGIA TREATMENT MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032

Hospital & Clinics
Ambulatory Surgery Centers
Others

GLOBAL NEURALGIA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Neuralgia Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Neuralgia Treatment Market Snippet by Treatment
- 2.1.2. Neuralgia Treatment Market Snippet by End Use
- 2.1.3. Neuralgia Treatment Market Snippet by Country
- 2.1.4. Neuralgia Treatment Market Snippet by Region
2.2. Competitive Insights

3. Neuralgia Treatment Key Market Trends

3.1. Neuralgia Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Neuralgia Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Neuralgia Treatment Market Opportunities
3.4. Neuralgia Treatment Market Future Trends

4. Neuralgia Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Neuralgia Treatment Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Neuralgia Treatment Market Landscape

6.1. Neuralgia Treatment Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Neuralgia Treatment Market - By Treatment

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
- 7.1.2. Drug Based
  - 7.1.2.1. Anticonvulsant Medicines
  - 7.1.2.2. Tricyclic Antidepressants
- 7.1.3. Surgery
  - 7.1.3.1. Radiofrequency Thermal Lesioning
  - 7.1.3.2. Stereotactic Radiosurgery
  - 7.1.3.3. Microvascular Decompression
  - 7.1.3.4. Others

8. Neuralgia Treatment Market - By End Use

8.1. Overview
- 8.1.1. Segment Share Analysis, By End Use, 2024 & 2032 (%)
- 8.1.2. Hospital & Clinics
- 8.1.3. Ambulatory Surgery Centers
- 8.1.4. Others

9. Neuralgia Treatment Market- By Geography

9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
9.2. North America
- 9.2.1. Overview
- 9.2.2. Neuralgia Treatment Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.2.6. U.S.
  - 9.2.6.1. Overview
  - 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.6.3. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.2.6.4. U.S. Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.2.7. Canada
  - 9.2.7.1. Overview
  - 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.7.3. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.2.7.4. Canada Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.3. Europe
- 9.3.1. Overview
- 9.3.2. Neuralgia Treatment Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.3.6. Germany
  - 9.3.6.1. Overview
  - 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.6.3. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.3.6.4. Germany Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.3.7. UK
  - 9.3.7.1. Overview
  - 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.7.3. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.3.7.4. UK Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.3.8. France
  - 9.3.8.1. Overview
  - 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.8.3. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.3.8.4. France Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.3.9. Italy
  - 9.3.9.1. Overview
  - 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.9.3. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.3.9.4. Italy Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.3.10. Spain
  - 9.3.10.1. Overview
  - 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.10.3. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.3.10.4. Spain Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.3.11. The Netherlands
  - 9.3.11.1. Overview
  - 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.11.3. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.3.11.4. The Netherlands Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.3.12. Sweden
  - 9.3.12.1. Overview
  - 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.12.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.3.12.4. Sweden Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.3.13. Russia
  - 9.3.13.1. Overview
  - 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.13.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.3.13.4. Russia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.3.14. Poland
  - 9.3.14.1. Overview
  - 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.14.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.3.14.4. Poland Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.3.15. Rest of Europe
  - 9.3.15.1. Overview
  - 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.15.3. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.3.15.4. Rest of the Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Neuralgia Treatment Key Manufacturers in Asia Pacific
- 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 9.4.5. APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.4.6. China
  - 9.4.6.1. Overview
  - 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.6.3. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.4.6.4. China Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.4.7. India
  - 9.4.7.1. Overview
  - 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.7.3. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.4.7.4. India Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.4.8. Japan
  - 9.4.8.1. Overview
  - 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.8.3. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.4.8.4. Japan Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.4.9. South Korea
  - 9.4.9.1. Overview
  - 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.9.3. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.4.9.4. South Korea Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.4.10. Australia
  - 9.4.10.1. Overview
  - 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.10.3. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.4.10.4. Australia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.4.11. Indonesia
  - 9.4.11.1. Overview
  - 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.11.3. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.4.11.4. Indonesia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.4.12. Thailand
  - 9.4.12.1. Overview
  - 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.12.3. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.4.12.4. Thailand Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.4.13. Philippines
  - 9.4.13.1. Overview
  - 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.13.3. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.4.13.4. Philippines Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.4.14. Rest of APAC
  - 9.4.14.1. Overview
  - 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.14.3. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.4.14.4. Rest of APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.5. Latin America (LATAM)
- 9.5.1. Overview
- 9.5.2. Neuralgia Treatment Key Manufacturers in Latin America
- 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 9.5.5. LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.5.6. Brazil
  - 9.5.6.1. Overview
  - 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.6.3. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.5.6.4. Brazil Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.5.7. Mexico
  - 9.5.7.1. Overview
  - 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.7.3. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.5.7.4. Mexico Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.5.8. Argentina
  - 9.5.8.1. Overview
  - 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.8.3. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.5.8.4. Argentina Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.5.9. Colombia
  - 9.5.9.1. Overview
  - 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.9.3. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.5.9.4. Colombia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.5.10. Rest of LATAM
  - 9.5.10.1. Overview
  - 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.10.3. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.5.10.4. Rest of LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa (MEA)
- 9.6.1. Overview
- 9.6.2. Neuralgia Treatment Key Manufacturers in Middle East and Africa
- 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4. MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 9.6.5. MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.6.6. Saudi Arabia
  - 9.6.6.1. Overview
  - 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.6.3. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.6.6.4. Saudi Arabia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.6.7. UAE
  - 9.6.7.1. Overview
  - 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.7.3. UAE Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.6.7.4. UAE Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.6.8. Israel
  - 9.6.8.1. Overview
  - 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.8.3. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.6.8.4. Israel Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.6.9. Turkey
  - 9.6.9.1. Overview
  - 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.9.3. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.6.9.4. Turkey Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.6.10. Algeria
  - 9.6.10.1. Overview
  - 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.10.3. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.6.10.4. Algeria Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.6.11. Egypt
  - 9.6.11.1. Overview
  - 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.11.3. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.6.11.4. Egypt Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 9.6.12. Rest of MEA
  - 9.6.12.1. Overview
  - 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.12.3. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 9.6.12.4. Rest of MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Neuralgia Treatment Industry

10.1. Competitive Benchmarking
- 10.1.1. Competitive Dashboard
- 10.1.2. Competitive Positioning
10.2. Company Profiles
- 10.2.1. GSK plc.
- 10.2.2. Pfizer Inc.
- 10.2.3. Biogen
- 10.2.4. Zydus Group (Cadila Healthcare Limited)
- 10.2.5. H. Lundbeck A/S
- 10.2.6. Novartis AG
- 10.2.7. Others